Which peptides actually help with sexual function and libido — and how do they differ from Viagra-class drugs?

The short answer

Sexual-health peptides are a smaller, better-defined category than most peptide verticals because one of them — PT-141 (bremelanotide) — actually has FDA approval. That single fact puts the category on firmer evidence footing than longevity or recovery peptides.

The three peptides that matter:

• PT-141 (bremelanotide) — FDA-approved as Vyleesi for premenopausal HSDD; acts on brain melanocortin pathways for arousal. The flagship.
• Kisspeptin — emerging human evidence for libido and sexual response; being studied for HSDD.
• Oxytocin — mixed evidence for arousal and pair-bonding; intranasal route most studied.

The key conceptual distinction that runs through this whole category: sexual-health peptides act on the arousal / desire pathway (brain), which is a different problem than the erectile / vascular pathway that Viagra-class drugs address. Getting this distinction right determines which tool fits which person.

For the broader pillar see the Sexual Health pillar hub.

Evidence tier framing: PT-141 sits at Tier 1–2 for its FDA-approved indication (premenopausal HSDD), Tier 3 for off-label uses. Kisspeptin is Tier 3 (emerging human RCT data). Oxytocin is Tier 3–4 (mixed human data). Melanotan II for sexual use is Tier 4 with notable safety concerns.

The arousal vs erectile distinction

Evidence tier: 2 — established pharmacology; the mechanistic distinction is well-characterized.

This is the single most important concept in the category, and it's the one most marketing gets wrong.

PDE5 inhibitors (Viagra/sildenafil, Cialis/tadalafil) act on vascular tissue. They inhibit the enzyme that breaks down cGMP, which keeps blood vessels in erectile tissue dilated. They improve the mechanics of an erection — but they require existing arousal to work. No desire signal, no effect.

PT-141 (bremelanotide) acts on melanocortin receptors (MC3R, MC4R) in the hypothalamus. It generates or amplifies the arousal signal itself — the upstream desire that PDE5 inhibitors then enable mechanically.

The practical implication: these treat different problems.

• If your issue is "I have desire but can't maintain an erection" → PDE5 inhibitor (erectile/vascular problem)
• If your issue is "I don't have the desire/arousal in the first place" → PT-141 may be relevant (arousal/desire problem)
• If both → they can be used together (with care; see the PT-141 complete guide)

Marketing that pitches "PT-141 is the new Viagra" is misleading — they're not substitutes, they're tools for different parts of the sexual-response cascade. Our arousal vs erectile dysfunction article goes deep on this.

PT-141 (bremelanotide) — the flagship

Evidence tier: 1–2 for FDA-approved premenopausal HSDD; Tier 3 for off-label use.

PT-141 is the only sexual-health peptide with FDA approval. Approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT trials (Kingsberg 2019 *Obstet Gynecol*, PMID 31599832).

Mechanism: melanocortin receptor agonism in the hypothalamus, generating central arousal signaling. Distinct from the vascular mechanism of PDE5 inhibitors.

Approved use: premenopausal women with acquired, generalized HSDD. Subcutaneous self-injection 45 minutes before anticipated activity (per the Vyleesi label) — though off-label protocols often use a longer 6–8 hour window.

Off-label uses (common, not FDA-approved): - Men with low libido / arousal-side dysfunction (especially TRT users with persistent low desire) - Postmenopausal women - General desire enhancement

Side effect profile: - Nausea (the dominant side effect; peaks 1–2 hours post-dose, dose-related) - Facial flushing - Headache - Transient blood pressure increase (the reason for cardiovascular screening before use)

The nausea is the main tolerability limiter. See PT-141 nausea management and the full PT-141 complete guide.

Kisspeptin — the emerging option

Evidence tier: 3 — growing human RCT data, not yet FDA-approved for sexual indications.

Kisspeptin is a neuropeptide that sits upstream of the entire reproductive hormone axis — it triggers GnRH release, which drives LH/FSH, which drives sex hormone production. Its role in sexual desire is being actively studied.

Recent human research (notably from the Imperial College London group) shows kisspeptin administration enhances sexual and attraction-related brain activity in both men and women, and improves sexual response in people with low desire (Mills 2023 *JAMA Netw Open*, PMID 36809469).

The kisspeptin appeal: it works at the level of the reproductive axis rather than just the arousal moment, and early data suggests it may help people with HSDD without the nausea burden of PT-141. It's not yet FDA-approved for any sexual indication and remains research-stage for this use.

For the female-specific angle see kisspeptin for female sexual health and sexual health peptides for women.

Oxytocin — bonding and arousal, mixed evidence

Evidence tier: 3–4 — mixed human data; intranasal route most studied.

Oxytocin is the "bonding hormone" — central to pair-bonding, social attachment, and orgasm physiology. Intranasal oxytocin has been studied for sexual function, relationship satisfaction, and arousal, with mixed results.

The honest evidence picture: oxytocin clearly plays a role in sexual and bonding physiology, but exogenous intranasal oxytocin has inconsistent effects on sexual outcomes in human trials. Some studies show benefit for arousal and relationship quality; others show no significant effect. The blood-brain-barrier penetration of intranasal oxytocin is itself debated.

Oxytocin's most defensible sexual-health use is for couples seeking enhanced bonding / intimacy rather than as a treatment for clinical dysfunction. See oxytocin nasal for sexual bonding.

Melanotan II — related but riskier

Evidence tier: 4 — sexual-arousal effects real, safety concerns notable.

Melanotan II is a broad melanocortin agonist (activates MC1R through MC5R) originally developed for tanning. Its MC4R activity produces sexual-arousal effects similar to PT-141 — which is unsurprising, because PT-141 (bremelanotide) was developed as a more-selective metabolite of melanotan II specifically to capture the sexual-arousal benefit with fewer off-target effects.

The melanotan II trade-off: broad receptor activity brings extra risks — pronounced tanning, new or changing moles (a melanoma-screening concern), stronger nausea, and appetite suppression. For sexual-health purposes specifically, PT-141 is the better-targeted, FDA-approved option.

Full comparison: Melanotan II vs PT-141 safety.

What about TRT and sexual health?

Evidence tier: 2 for testosterone's role; Tier 3 for peptide adjuncts.

Testosterone replacement therapy (TRT) restores serum testosterone, which improves libido for many men with hypogonadism. But TRT doesn't always restore the full arousal-response pathway, especially when the dysfunction is central (brain-level) rather than purely hormonal.

For TRT users with persistent low desire despite adequate testosterone levels: - The issue is often arousal-side, not testosterone-deficiency - PT-141 addresses the central arousal pathway directly - PDE5 inhibitors address the vascular side if that's the limiter - Each solves a different part of the problem

This is a common and underserved scenario. See the TRT + sexual health article for the full decision framework.

What doesn't have evidence

Evidence tier: 4–5 — marketing-driven claims without human outcome data.

Several peptides get marketed for sexual health without the evidence to support it:

• "Sexual enhancement peptide stacks" — bundling PT-141 with unproven additions
• Generic "libido peptides" that aren't PT-141, kisspeptin, or oxytocin
• Growth-hormone peptides marketed for sexual function — sermorelin and similar improve sleep and body composition, which can indirectly help, but they aren't sexual-health peptides per se. See sermorelin for libido for the honest framing of the indirect pathway.

The evidence-supported sexual-health peptide list is short: PT-141 (FDA-approved), kisspeptin (emerging), oxytocin (mixed). Everything else is mechanism plus marketing.

A note on PSSD

Evidence tier: 4 — emerging area, limited evidence, included for completeness.

Post-SSRI Sexual Dysfunction (PSSD) is a condition where sexual dysfunction persists after stopping SSRI antidepressants. It's a genuine and underrecognized condition. Some PSSD patients explore peptide interventions (including PT-141 and others) as part of recovery attempts.

The evidence for peptides specifically in PSSD is thin, and PSSD is a complex condition that warrants specialist involvement rather than self-experimentation. See PSSD recovery for the careful framing.

Limitations

This is an evidence review, not personalized medical advice.

• Cardiovascular screening before PT-141 — it transiently raises blood pressure; clearance from a physician matters, especially for anyone with cardiovascular risk factors.
• Drug interactions — PT-141 with certain blood pressure medications warrants caution.
• Pregnancy and breastfeeding are contraindications.
• PSSD and complex sexual dysfunction warrant specialist evaluation, not self-experimentation.
• Melanotan II carries melanoma-screening concerns — dermatology monitoring if used.
• Vendor sourcing for non-Vyleesi PT-141 and the other peptides carries real safety risk. Verify via Finnrick before use.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Sexual-health peptides are a smaller, better-evidenced category than most peptide verticals, anchored by PT-141's FDA approval. The category-defining concept is the arousal-vs-erectile distinction: PT-141 and kisspeptin address desire/arousal (brain), PDE5 inhibitors address erectile mechanics (vascular). They're complements, not substitutes.

For most users: PT-141 if the issue is low desire/arousal (FDA-approved for women, off-label for men), PDE5 inhibitors if the issue is erectile mechanics, both if both. Kisspeptin is the emerging option worth tracking. Oxytocin is for bonding more than dysfunction. Skip the "sexual enhancement stacks" — the evidence-supported list is three peptides, not ten.

What we'll be tracking

• Kisspeptin progression toward FDA approval for HSDD
• Expanded PT-141 indications (postmenopausal women, men)
• Oxytocin sexual-function trials with better methodology
• PSSD treatment research

Related on this site

• PT-141 complete guide
• Arousal vs erectile dysfunction — why Viagra and PT-141 differ
• Sexual health peptides for women
• TRT + sexual health: when peptides help
• PT-141 nausea management
• Kisspeptin for female sexual health
• Oxytocin nasal for sexual bonding
• Melanotan II vs PT-141 safety
• Sermorelin for libido
• PSSD recovery
• Main PT-141 peptide page
• Sexual Health pillar hub
• Finnrick PT-141 vendor testing

References

• Kingsberg SA, Clayton AH, Portman D, et al. 2019. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstet Gynecol. 134(5):899-908. PMID 31599832 — pivotal PT-141 FDA-approval trials.
• Mills EG, Ertl N, Wall MB, et al. 2023. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder. JAMA Netw Open. 6(2):e2254313. PMID 36809469 — kisspeptin sexual-response evidence.
• Clayton AH, Althof SE, Kingsberg S, et al. 2016. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 12(3):325-337. PMID 27181790 — PT-141 dose-finding data.
• Behnia B, Heinrichs M, Bergmann W, et al. 2014. Differential effects of intranasal oxytocin on sexual experiences and partner interactions in couples. Horm Behav. 65(3):308-318. PMID 24503450 — intranasal oxytocin sexual-function data (mixed-effects example).
• US Food and Drug Administration. 2019. Vyleesi (bremelanotide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf — regulatory label and approved-use reference.
• Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. 2003. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 994:96-102. PMID 12851303 — foundational PT-141 mechanism paper.